Literature DB >> 18613809

The safety of disulfiram for the treatment of alcohol and cocaine dependence in randomized clinical trials: guidance for clinical practice.

Robert Malcolm1, M Foster Olive, William Lechner.   

Abstract

BACKGROUND: Disulfiram has demonstrated efficacy in six randomized clinical trials for the treatment of cocaine dependence, but is rarely used in clinical settings because of safety concerns.
OBJECTIVE: What are the common and serious side effects of disulfiram in cocaine-dependent individuals with and without alcohol dependence in randomized clinical trials?
METHODS: We located Phase I and II randomized trials that discussed the safety of disulfiram. RESULTS/
CONCLUSIONS: In randomized clinical trials that eliminated subjects with serious cardiovascular, hepatic, and psychiatric disorders, the most frequent side effects of disulfiram over placebo or index groups include headaches, fatigue, sleepiness, and anxiety. Disulfiram in a dose of <or= 250 mg/day led to only mild interactions with alcohol. When patients are screened for medical and psychiatric stability, and are evaluated for drug interactions, disulfiram has an acceptable side-effect profile for the treatment of cocaine dependence with or without alcohol dependence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18613809     DOI: 10.1517/14740338.7.4.459

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  16 in total

1.  Cystamine and Disulfiram Inhibit Human Transglutaminase 2 via an Oxidative Mechanism.

Authors:  Brad A Palanski; Chaitan Khosla
Journal:  Biochemistry       Date:  2018-03-28       Impact factor: 3.162

Review 2.  [Relapse prevention in alcohol dependence: acamprosate and naltrexone as a combined pharmacological strategy].

Authors:  M Gahr; M A Kölle; C Schönfeldt-Lecuona
Journal:  Nervenarzt       Date:  2013-05       Impact factor: 1.214

3.  A double-blind, placebo-controlled assessment of the safety of potential interactions between intravenous cocaine, ethanol, and oral disulfiram.

Authors:  John D Roache; Roberta Kahn; Thomas F Newton; Christopher L Wallace; William L Murff; Richard De La Garza; Oscar Rivera; Ann Anderson; Jurij Mojsiak; Ahmed Elkashef
Journal:  Drug Alcohol Depend       Date:  2011-06-21       Impact factor: 4.492

4.  A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells.

Authors:  Ilana Chefetz; Edward Grimley; Kun Yang; Linda Hong; Ekaterina V Vinogradova; Radu Suciu; Ilya Kovalenko; David Karnak; Cynthia A Morgan; Mikhail Chtcherbinine; Cameron Buchman; Brandt Huddle; Scott Barraza; Meredith Morgan; Kara A Bernstein; Euisik Yoon; David B Lombard; Andrea Bild; Geeta Mehta; Iris Romero; Chun-Yi Chiang; Charles Landen; Benjamin Cravatt; Thomas D Hurley; Scott D Larsen; Ronald J Buckanovich
Journal:  Cell Rep       Date:  2019-03-12       Impact factor: 9.423

5.  Structural basis for inactivation of Giardia lamblia carbamate kinase by disulfiram.

Authors:  Andrey Galkin; Liudmila Kulakova; Kap Lim; Catherine Z Chen; Wei Zheng; Illarion V Turko; Osnat Herzberg
Journal:  J Biol Chem       Date:  2014-02-20       Impact factor: 5.157

Review 6.  Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence.

Authors:  Julia M A Sinclair; Sophia E Chambers; Celia J Shiles; David S Baldwin
Journal:  Drug Saf       Date:  2016-07       Impact factor: 5.606

Review 7.  Anti-relapse medications: preclinical models for drug addiction treatment.

Authors:  Noushin Yahyavi-Firouz-Abadi; Ronald E See
Journal:  Pharmacol Ther       Date:  2009-08-13       Impact factor: 12.310

8.  Targeting liver aldehyde dehydrogenase-2 prevents heavy but not moderate alcohol drinking.

Authors:  Adrien Guillot; Tianyi Ren; Tony Jourdan; Robert J Pawlosky; Elaine Han; Seung-Jin Kim; Li Zhang; George F Koob; Bin Gao
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-02       Impact factor: 11.205

9.  A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence.

Authors:  Kathleen M Carroll; Charla Nich; Nancy M Petry; Dorothy A Eagan; Julia M Shi; Samuel A Ball
Journal:  Drug Alcohol Depend       Date:  2016-01-13       Impact factor: 4.492

Review 10.  mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse.

Authors:  Meriem Gaval-Cruz; David Weinshenker
Journal:  Mol Interv       Date:  2009-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.